Stockscreener 앱 받기
8.26
0.61%
0.05
시간 외 거래:
8.16
-0.10
-1.21%
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 - Business Wire
Glass Lewis Supports Aurinia’s Proposals for 2025 AGM - TipRanks
ISS Endorses Aurinia’s Proposals for 2025 Annual Meeting - TipRanks
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - Business Wire
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - BioSpace
Aurinia Pharmaceuticals (AUPH) Gains Support from ISS for Board - GuruFocus
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (NASDAQ:AUPH) - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting - Business Wire
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN
Aurinia Sues Galenicum to Block Copies of Lupkynis Kidney Drug - Bloomberg Law News
Aurinia Sues Lotus Alleging Lupus Drug Patent Infringement - Law360
High Growth Tech Stocks To Watch In The US Market - simplywall.st
Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)? - Yahoo
Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues - simplywall.st
Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
(AUPH) Trading Signals - news.stocktradersdaily.com
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
Aurinia Pharmaceuticals Announces Financial Growth and Pipeline Progress in 2024 - Zenopa
Principal Financial Group Inc. Sells 1,325 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome - marketscreener.com
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 - Investing.com India
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 By Investing.com - Investing.com UK
Commit To Purchase Aurinia Pharmaceuticals At $7, Earn 17.4% Annualized Using Options - Nasdaq
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point - Yahoo Finance
Aurinia Pharmaceuticals stock climbs on insider buying - MSN
Aurinia Pharmaceuticals CEO Peter Greenleaf sells shares worth $2.87 million - Investing.com India
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 - Investing.com Australia
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 By Investing.com - Investing.com South Africa
Major Investment Alert: Kevin Tang Boosts Stake in Aurinia Pharmaceuticals - TipRanks
Aurinia Pharmaceuticals’ chief medical officer sells $97,912 in stock - Investing.com
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 - Investing.com India
Aurinia Pharmaceuticals EVP Stephen Robertson sells shares worth $975,223 - Investing.com
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - Nasdaq
Objective long/short (AUPH) Report - Stock Traders Daily
LAWSUITS FILED AGAINST ABBV, SDIG and AUPHJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Atria Wealth Solutions Inc. Buys Shares of 15,000 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Simply Wall St
0.39%
3.66%
자본화:
|
볼륨(24시간):